Підписатись
Vladimir Semiglazov
Vladimir Semiglazov
Petrov Research Institute of Oncology
Немає підтвердженої електронної адреси
Назва
Посилання
Посилання
Рік
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
61442005
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
42752013
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
42392014
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised …
L Gianni, T Pienkowski, YH Im, L Roman, LM Tseng, MC Liu, A Lluch, ...
The lancet oncology 13 (1), 25-32, 2012
26252012
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ...
New England journal of medicine 372 (8), 724-734, 2015
22542015
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
22162015
Polychemotherapy for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 352 (9132), 930-942, 1998
21551998
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thürlimann, HJ Senn
Annals of oncology 20 (8), 1319-1329, 2009
19522009
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ...
The Lancet 379 (9816), 633-640, 2012
15672012
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer …
L Gianni, W Eiermann, V Semiglazov, A Manikhas, A Lluch, S Tjulandin, ...
The Lancet 375 (9712), 377-384, 2010
15582010
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
12242017
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo …
SM Swain, SB Kim, J Cortés, J Ro, V Semiglazov, M Campone, E Ciruelos, ...
The lancet oncology 14 (6), 461-471, 2013
11272013
SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN. 2.
O Abe, R Abe, K Asaishi, K Enomoto, T Hattori, Y Ino, K Kikuchi, ...
Lancet 339 (8785), 71-85, 1992
10871992
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
M Kaufmann, GN Hortobagyi, A Goldhirsch, S Scholl, A Makris, ...
Journal of Clinical Oncology 24 (12), 1940-1949, 2006
9322006
Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
W Eiermann, S Paepke, J Appfelstaedt, A Llombart-Cussac, J Eremin, ...
Annals of oncology 12 (11), 1527-1532, 2001
9262001
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre …
L Gianni, T Pienkowski, YH Im, LM Tseng, MC Liu, A Lluch, ...
The lancet oncology 17 (6), 791-800, 2016
8672016
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study
B Leyland-Jones, V Semiglazov, M Pawlicki, T Pienkowski, S Tjulandin, ...
Journal of Clinical Oncology 23 (25), 5960-5972, 2005
8192005
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer
J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, ...
Journal of Clinical Oncology 27 (16), 2630-2637, 2009
8102009
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ...
The lancet oncology 12 (3), 236-244, 2011
7972011
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …
SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...
The Lancet Oncology 21 (4), 519-530, 2020
5772020
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20